Evidence map›Paper›PMID 38496907›Full record

ArticleNeuro-oncology practice2024

Final report of the phase II NEXT/CNS-GCT-4 trial: GemPOx followed by marrow-ablative chemotherapy for recurrent intracranial germ cell tumors.

Margaret Shatara, Megan Blue, Joseph Stanek, Yin A Liu, Daniel M Prevedello, Pierre Giglio, Vinay K Puduvalli, Sharon L Gardner, Jeffrey C Allen, Kenneth K Wong and 8 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Neuro-oncology practice, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.9field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 10 institutions in 1 country.

Margaret ShataraDivision of Hematology and Oncology, St. Louis Children's Hospital, Washington University School of Medicine, St. Louis, Missouri, USA.ORCID https://orcid.org/0000-0001-5821-6216
Megan BlueDivision of Hematology, Oncology, Blood and Marrow Transplant, Nationwide Children's Hospital and Ohio State University College of Medicine, Columbus, Ohio, USA.
Joseph StanekDivision of Hematology, Oncology, Blood and Marrow Transplant, Nationwide Children's Hospital and Ohio State University College of Medicine, Columbus, Ohio, USA.ORCID https://orcid.org/0000-0003-1630-2102
Yin A LiuDepartments of Ophthalmology, Neurology, and Neurosurgery, University of California, Davis, Sacramento, California, USA.
Daniel M PrevedelloDepartment of Neurological Surgery, Ohio State University Wexner Medical Center, Columbus, Ohio, USA.
Pierre GiglioDivision of Neuro-Oncology, Ohio State University Wexner Medical Center, James Cancer Center, Columbus, Ohio, USA.ORCID https://orcid.org/0000-0001-5165-0984
Vinay K PuduvalliDepartment of Neuro-oncology, MD Anderson Cancer Center, Houston, Texas, USA.ORCID https://orcid.org/0000-0001-8396-9500
Sharon L GardnerDepartment of Pediatrics, New York University Grossman School of Medicine, New York, New York, USA.
Jeffrey C AllenDepartment of Pediatrics, New York University Grossman School of Medicine, New York, New York, USA.
Kenneth K WongDivision of Hematology and Oncology, Cancer and Blood Disease Institute, Children's Hospital Los Angeles and Keck School of Medicine of University of Southern California, Los Angeles, California, USA.
Marvin D NelsonDepartment of Radiology, Children's Hospital of Los Angeles, Los Angeles, California, USA.
Floyd H GillesDepartment of Pathology, Children's Hospital of Los Angeles, Los Angeles, California, USA.
Roberta H AdamsPhoenix Children's Center for Cancer & Blood Disorders, University of Arizona School of Medicine-Phoenix, and Mayo Clinic, Arizona, USA.
Jasmine PaulyDivision of Hematology and Oncology, Cancer and Blood Disease Institute, Children's Hospital Los Angeles, California, USA.
Katrina O'HalloranDivision of Hematology and Oncology, Cancer and Blood Disease Institute, Children's Hospital Los Angeles and Keck School of Medicine of University of Southern California, Los Angeles, California, USA.
Ashley S MargolDivision of Hematology and Oncology, Cancer and Blood Disease Institute, Children's Hospital Los Angeles and Keck School of Medicine of University of Southern California, Los Angeles, California, USA.
Girish DhallDivision of Pediatric Hematology/Oncology, Children's Hospital of Alabama and the University of Alabama at Birmingham, Birmingham, Alabama, USA.ORCID https://orcid.org/0000-0002-4918-0167
Jonathan L FinlayDivision of Hematology, Oncology, Blood and Marrow Transplant, Nationwide Children's Hospital and Ohio State University College of Medicine, Columbus, Ohio, USA.
Children's Hospital of Los Angeles · USNationwide Children's Hospital · USUniversity of Southern California · USNew York University · USThe Ohio State University Wexner Medical Center · USChildren's of Alabama · USSt. Louis Children's Hospital · USThe University of Texas MD Anderson Cancer Center · USUniversity of Arizona · USUniversity of California, Davis · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Patients with relapsed intracranial germinoma can achieve durable remission with standard chemotherapy regimens and/or reirradiation; however, innovative therapies are required for patients with relapsed and/or refractory intracranial nongerminomatous germ cell tumors (NGGCTs) due to their poor prognosis. Improved outcomes have been reported using reinduction chemotherapy to achieve minimal residual disease, followed by marrow-ablative chemotherapy (HDCx) with autologous hematopoietic progenitor cell rescue (AuHPCR). We conducted a phase II trial evaluating the response and toxicity of a 3-drug combination developed for recurrent intracranial germ cell tumors consisting of gemcitabine, paclitaxel, and oxaliplatin (GemPOx). Methods: A total of 9 patients with confirmed relapsed or refractory intracranial GCT were enrolled after signing informed consent, and received at least 2 cycles of GemPOx, of which all but 1 had relapsed or refractory NGGCTs. One patient with progressive disease was found to have pathologically confirmed malignant transformation to pure embryonal rhabdomyosarcoma (without GCT elements), hence was ineligible and not included in the analysis. Patients who experienced sufficient responses proceeded to receive HDCx with AuHPCR. Treatment response was determined based on radiographic tumor assessments and tumor markers. Results: A total of 7 patients achieved sufficient response and proceeded with HDCx and AuHPCR, and 5 subsequently received additional radiotherapy. A total of 2 patients developed progressive disease while receiving GemPOx. Myelosuppression and transaminitis were the most common treatment-related adverse events. With a mean follow-up of 44 months, 4 patients (3 NGGCTs, 1 germinoma) are alive without evidence of disease. Conclusions: GemPOx demonstrates efficacy in facilitating stem cell mobilization, thus facilitating the feasibility of both HDCx and radiotherapy.

Indexed as

GemPOxlong-term survivalobjective response rateoutcomesrelapsed intracranial GCTs

Identifiers

PMID38496907
PMCPMC10940828
OpenAlexW4387656636

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.